A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate
Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical research study is to provide dasatinib treatment to patients
with advanced chronic myelogenous leukemia (CML) or Philadelphia chromosome positive acute
lymphoblastic leukemia (Ph+ ALL) who no longer can tolerate treatment with imatinib. The
safety of the treatment will also be studied.